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Objective: Stress to the endoplasmic reticulum (ER) and inﬂammatory cytokines induce expression and
activity of matrix metalloproteinase 13 (MMP13). Since a synthetic agent, salubrinal, is known to alle-
viate ER stress and attenuate nuclear factor kappa B (NFkB) signaling, we addressed a question whether
upregulation of MMP13 by ER stress and cytokines is suppressed by administration of salubrinal.
Methods: Using C28/I2 human chondrocytes, we applied ER stress with tunicamycin and inﬂammatory
distress with tumor necrosis factor a (TNFa) and interleukin 1b (IL1b). RNA interference with siRNA
speciﬁc to NFkB p65 (RelA) was employed to examine a potential involvement of NFkB signaling in
salubrinal’s action in regulation of MMP13. We also employed primary human chondrocytes and eval-
uated MMP13 activity.
Results: The result showed that tunicamycin activated p38 mitogen-activated protein kinase (MAPK),
while inﬂammatory cytokines activated p38 MAPK and NFkB. In both cases, salubrinal signiﬁcantly
reduced expression and activity of MMP13. Silencing NFkB reduced inﬂammatory cytokine-driven
upregulation of MMP13 activity.
Conclusions: The results demonstrate that salubrinal downregulates expression and activity MMP13
through p38 and NFkB signaling, suggesting its potential usage to treat degenerative diseases such as
osteoarthritis.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
One of the most predominant collagenases in destruction of the
articular cartilage is matrix metalloproteinase 13 (MMP13)1. The
articular cartilage is sensitive to environmental and cellular stresses
including mechanical loading, stress to the endoplasmic reticulum
(ER), and inﬂammatory cytokines2,3. Excessive loading is detri-
mental to maintenance of joint tissues, but immobilization is also
harmful and activates MMP134. The stress to the ER is reported to
induce inﬂammatory responses and cellular apoptosis5,6. It acti-
vates p38 mitogen-activated protein kinase (MAPK) and activates
MMP137. Inﬂammatory cytokines such as interleukin 1b (IL1b) and
tumor necrosis factor a (TNFa) are known to be a prime inducer of
MMP13 through pathways involving MAPK and nuclear factor
kappa B (NFkB)8,9. To preserve arthritic joint tissues, blocking
degenerative actions of MMP13 is imperative. The aim of this study: H. Yokota, Department of
University Indianapolis, 723
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s Research Society International. Pis to investigate a potential role of salubrinal, a synthetic chemical
agent, in downregulation of MMP13 in the presence of the stress to
the ER as well as inﬂammatory cytokines.
Salubrinal is 3-phenyl-N-[2,2,2-trichloro-1-[[(8-quinolinyla
mino)thioxomethyl]amino]ethyl]-2-propenamide (C21H17Cl3N4OS,
480 Da), which acts as an inhibitor of a phosphatase selective to
eukaryotic translation initiation factor 2a (eIF2a)10. The elevation of
the level of phosphorylated eIF2a leads to expression of activating
transcription factor 4 (ATF4)11, which is one of the key transcription
factors in bone development12. Salubrinal is shown to accelerate
healing of bone wounds in mice and stimulates differentiation of
osteoblasts13,14. An intriguing question is salubrinal’s potential ef-
fects on other skeletal tissues such as the cartilage. Administration
of salubrinal may prevent osteoporotic bone loss15, but it should
not generate detrimental outcomes to joint tissues. Little has been
known, however, about its effects on preservation of joint tissues, in
particular the potential role in the regulation of MMP13 in
chondrocytes.
In this study we addressed a pair of questions using a human
chondrocyte cell line, C28/I2: Does salubrinal decrease the mRNA
expression of MMP13 in the presence of tunicamycin that is an
inducer to the stress to the ER? If yes, does salubrinal also suppress
inﬂammatory cytokine induced upregulation of MMP13?ublished by Elsevier Ltd. All rights reserved.
Table I
Real-time PCR primers used in this study
Target Forward primer Backward primer
CHOP 50-TGCCTTTCTCTTCG
GACACT-30
50-TGTGACCTCTGCTGGTTCTG-30
MMP1 50-TACACGGATACCCCA
AGGACAT-30
50-CCTCAGAAAGAGCAGCATCGA-30
MMP2 50-GATACCCCTTTGACG
GTAAGGA-30
50-CCTTCTCCCAAGGTCCATAGC-30
MMP3 50-CTGGACTCCGACAC
TCTGGA-30
50-CAGGAAAGGTTCTGAAGTGACC-30
MMP13 50-AATATCTGAACTGGG
TCTTCCAAAA-30
50-CAGACCTGGTTTCCTGAGAACAG-30
MMP14 50-GGCTACAGCAATAT
GGCTACC-30
50-GATGGCCGCTGAGAGTGAC-30
GAPDH 50-GCACCGTCAAGGCT
GAGAAC-30
50-ATGGTGGTGAAGACGCCAGT-30
K. Hamamura et al. / Osteoarthritis and Cartilage 21 (2013) 764e772 765Tunicamycin is an inhibitor of N-linked glycosylation and the for-
mation of N-glycosidic protein-carbohydrate linkages16. Since
activation of MMP13 is mediated by p38 MAPK and NFkB signaling
pathways, our hypothesis was that salubrinal reduces MMP13
mRNA expression induced by the stress to the ER and inﬂammatory
cytokines through reducing the activation of p38 and/or NFkB. To
test any linkage among signaling with eIF2a, p38 MAPK, and NFkB,
we examined a time sequence of phosphorylation events of these
molecules.We also employed siRNA speciﬁc to NFkB p65 (RelA) and
evaluated its effects on the phosphorylation of eIF2a and p38
MAPK, as well as MMP13 activity.A B
C
D E
Fig. 1. Responses of C28/I2 chondrocytes to tunicamycin and salubrinal. (A) Cell mortality ra
reduced by salubrinal. (D) Relative mRNA abundance of CHOP. (E) Relative mRNA abundanMaterials and methods
Cell culture
Human chondrocyte cell line, C28/I2, was used throughout this
study, and human primary chondrocytes (PC136121A1-C, Asterand)
was also used for evaluating MMP13 activity as well as signaling
mediated by p38MAPK and NFkB. Cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 10% fetal bovine
serum and antibiotics (Invitrogen). Cell mortality and live cell
numbers were determined 12 or 24 h after the treatment with 1 mg/
ml tunicamycin (Sigma), 10 ng/ml TNFa (R&D Systems), or 1 ng/ml
IL1b (R&D Systems) in response to 0.1e20 mM salubrinal (TOCRIS
bioscience). All experiments involving IL1b and TNFa stimulation
were performed after 10 h serum-free conditions. Cells were
stained with trypan blue and the numbers of live and dead cells
were counted using a hemacytometer.
Quantitative real-time polymerase chain reaction (PCR)
Total RNA was extracted using an RNeasy Plus kit (Qiagen).
Reverse transcription was conducted with high capacity cDNA
reverse transcription kits (Applied Biosystems), and quantitative
real-time PCR was performed using ABI 7500 with Power SYBR
green PCR master mix kits (Applied Biosystems). We evaluated
mRNA levels of CHOP, MMP1, MMP2, MMP3, MMP13, and MMP14
with the PCR primers listed in Table I. The relative mRNAtio. (B) Relative cell number. (C) Elevation of the level of cleaved caspase 3, which was
ce of MMP13.
K. Hamamura et al. / Osteoarthritis and Cartilage 21 (2013) 764e772766abundance for the selected genes with respect to the level of
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was
expressed as a ratio of Streated/Scontrol, where Streated ¼ mRNA level
for the cells treated with chemical agents, and Scontrol¼mRNA level
for control cells.
Immunoblots
Cells were lysed in a radioimmunoprecipitation lysis buffer con-
taining protease inhibitors (Santa Cruz) and phosphatase inhibitors
(Calbiochem). Isolated proteins were fractionated using sodium
dodecyl sulfate gels and electro-transferred to Immobilon-P mem-
branes (Millipore). The membrane was incubated with primary
antibodies followed by secondary antibodies conjugated with
horseradish peroxidase (Cell Signaling). We used antibodies against
ATF4 (Santa Cruz), p-eIF2a (Thermo), eIF2a, cleaved and total caspase
3,p38 andp-p38MAPK, p-IKKa/b, IkB,NFkBp65andp-NFkBp65 (Cell
Signaling), and b-actin (Sigma). Protein levels were assayed using a
SuperSignal west femto maximum sensitivity substrate (Thermo).
MMP13 activity
MMP13 sensitive ﬂuorogenic peptide probe (Gly-Pro-Leu-Gly-
Val-Arg-Gly-Cys-Gly-Gly) was prepared using a microwave pep-
tide synthesizer (CEM Discover, SPS) following standard solidA
B
C
Fig. 2. Western blot analysis for eIF2a, p38 MAPK, and NFkB to tunicamycin. (A) Elevation
suppression by 10 mM salubrinal. (C) No effects on NFkB signaling by tunicamycin. The positi
ml IL1b.phase peptide synthesis procedures17. Fluorophore 5(6)ROX and
its thiol reactive quencher (QXL-610-vinylsulfone) were labeled
at the peptide N-terminus and added cysteine residue, respec-
tively. The peptide probe was puriﬁed using a reverse phase high
performance liquid chromatography (PerkinElmer Flexar). The
isolated proteins were incubated with the ﬂuorescent substrates
in the reaction buffer at room temperature for 2 h. A reaction
buffer consisted of 50 mM TriseHCl (pH 7.6), 150 mM NaCl, 5 mM
CaCl2, and 0.2 mM sodium azide. Fluorescent intensity, a measure
of enzymatic activity, was measured at 560/590 nm (excitation/
emission). The activity levels were determined using a control
solution without consisting of any protein sample, and normal-
ized using the concentrations of total proteins.
Knockdown of NFkB p65 (RelA) by siRNA
Cells were treated with siRNA speciﬁc to NFkB p65 (RelA)
(Invitrogen). The targeted RelA sequence was 50-GCCCUAUCC-
CUUUACGUCA TT-30, while a negative siRNA (Silencer Select #1,
Invitrogen) was used as a nonspeciﬁc control. C28/I2 cells were
transiently transfected with RelA or control siRNA in Opti-MEM I
mediumwith Lipofectamine RNAiMAX (Invitrogen). Six hours later,
the medium was replaced by regular culture medium. The efﬁ-
ciency of silencing RelA was assessed with immunoblotting 48 h
after the transfection.of p-eIF2a and ATF4. (B) Upregulation of p-p38 MAPK by tunicamycin and its partial
ve controls for p-IKKa/b and p-NFkB are shown in response to 10 ng/ml TNFa and 1 ng/
K. Hamamura et al. / Osteoarthritis and Cartilage 21 (2013) 764e772 767Statistical analysis
At least three-independent experiments were conducted and
data points were presented with 95% conﬁdence intervals (CIs). For
comparison among multiple samples, analysis of variance followed
by post ad hoc tests was conducted. The single and double asterisks
indicate P < 0.05 and P < 0.01 in comparison to treatments with
tunicamycin, TNFa, or IL1b, respectively. The single and double
daggers indicate P < 0.05 and P < 0.01 in comparison to control
without any treatment, respectively.A
C D
F
G
Fig. 3. Responses of C28/I2 and primary chondrocytes to TNFa. (A) Cell mortality ratio in C28
mRNA abundance to TNFa in C28/I2 chondrocytes. (D) MMP13 activity induced by TNFa and
TNFa and suppressed by 5 mM salubrinal in primary chondrocytes. (F) Elevation of p-p38 MA
by TNFa and partial de-activation by salubrinal in C28/I2 chondrocytes and primary chondResults
Suppression of tunicamycin-induced cell death and expression of
MMP13 mRNA by salubrinal
Administration of 1 mg/ml tunicamycin increased cell mortality
ratio from 4.8% (95% CI 2.7e6.9%) to 13.6% (95% CI 10.6e16.6%,
P ¼ 0.00049) and reduced the relative cell number to 33.3% of the
control cells (P ¼ 0.0074) [Fig. 1(A and B)]. Incubation of cells with
salubrinal signiﬁcantly reduced cell mortality ratio, although theE
B
H
/I2 chondrocytes. (B) Relative cell number in C28/I2 chondrocytes. (C) Relative MMP13
suppressed by 5 mM salubrinal in C28/I2 chondrocytes. (E) MMP13 activity induced by
PK by TNFa, which is partially decreased by 5 mM salubrinal. (GeH) Activation of NFkB
rocytes, respectively.
K. Hamamura et al. / Osteoarthritis and Cartilage 21 (2013) 764e772768number of live cells was not signiﬁcantly different. The expression
level of the cleaved caspase 3 was elevated by tunicamycin and
reduced by salubrinal at 1e20 mM in a dosage dependent manner
[Fig. 1(C)]. Tunicamycin also elevated the mRNA levels of CHOP and
MMP13, but their levels were signiﬁcantly suppressed by salubrinal
at 5, 10, and 20 mM [Fig. 1(D and E)].A
B
D
C
E
F
Fig. 4. Responses of C28/I2 chondrocytes to IL1b. (A) Cell mortality ratio. (B) Relative cell n
induced by IL1b and suppressed by 10 mM salubrinal. (E) Elevation of p-p38 MAPK by IL1b,
partial suppression by 10 mM salubrinal.Reduction in the phosphorylation of p38 MAPK by salubrinal in
tunicamycin treated chondrocytes
Tunicamycin increased the level of eIF2a phosphorylation
(p-eIF2a) at 1 h, followed by an elevation in the level of ATF4 at 3 h
[Fig. 2(A)]. Co-incubation with tunicamycin and salubrinal alsoumber. (C) Relative MMP13 mRNA abundance in response to IL1b. (D) MMP13 activity
which is partially decreased by 10 mM salubrinal. (F) Activation of NFkB by IL1b and its
K. Hamamura et al. / Osteoarthritis and Cartilage 21 (2013) 764e772 769presented an increase in p-eIF2a and ATF4 [Fig. 2(B)]. Tunicamycin
also induced phosphorylation of p38 MAPK (p-p38 MAPK) at 1 and
2 h, while administration of 10 mM salubrinal suppressed the
tunicamycin-induced increase in p-p38 MAPK [Fig. 2(B)]. Although
NFkB signaling is reported to be involved in regulation of MMP13,
tunicamycin did not alter the level of phosphorylated NFkB p65 (p-
NFkB) or its inhibitor, IkB [Fig. 2(C)].
Suppression of TNFa-induced MMP13 mRNA by salubrinal through
p38 MAPK and NFkB
Incubation with 10 ng/ml TNFa did not signiﬁcantly alter cell
mortality ratio and the total cell numbers regardless of salubrinal
administration at 5 or 10 mM [Fig. 3(A and B)]. However, TNFa
increased the level of MMP13 mRNA by 2.0 fold (95% CI 1.5e2.5
fold, P ¼ 0.0013) and this increase was signiﬁcantly reduced by 5e
10 mM salubrinal (5 mM: P ¼ 0.0074, 10 mM: P ¼ 0.0045) [Fig. 3(C)].A B
C
Fig. 5. Effects of silencing NFkB p65 (RelA) in C28/I2 chondrocytes. (A) Western blots for s
(C) Suppression of TNFa driven upregulation of MMP13 activity by silencing NFkB p65.Furthermore, the activity level of MMP13 was increased by TNFa
and suppressed by salubrinal in C28/I2 chondrocytes [Fig. 3(D)] and
primary chondrocytes [Fig. 3(E)]. TNFa elevated the level of p-p38
MAPK and p-NFkB p65 in C28/I2 chondrocytes [Fig. 3(F and G)] and
primary chondrocytes [Fig. 3(H)]. An increase in p-NFkB p65 coin-
cided with an increase in p-IKKa/b and a decrease in IkB, which is
an inhibitor of NFkB. In response to 5 mM salubrinal, the levels of p-
p38MAPK, p-IKKa/b, and p-NFkB p65were decreased at 15min. No
changes in the level of p-eIF2a were observed within 60 min (data
not shown).
Suppressive effects of salubrinal on IL1b-induced upregulation of
MMP13
Consistentwith the results with TNFa, the effects of salubrinal on
IL1b-induced upregulation of MMP13 were also medicated by p38
MAPK and NFkB. Cell mortality and cell numbers were notilencing NFkB p65. (B) Effects of silencing RelA on p-NFkB, p-p38 MAPK and p-eIF2a.
K. Hamamura et al. / Osteoarthritis and Cartilage 21 (2013) 764e772770signiﬁcantly changed in response to 1 ng/ml IL1b with and without
5e10 mM salubrinal [Fig. 4(A and B)]. Compared to the control cells
without any treatment, the level of MMP13mRNAwas increased 2.0
fold (95% CI 1.5e2.4 fold, P ¼ 0.0008) by IL1b and this increase was
signiﬁcantly reduced by 5e10 mMsalubrinal (5 mM: P¼ 0.019,10 mM:
P¼ 0.0049) [Fig. 4(C)]. In theMMP13 activity assay,10 mM salubrinalA
C
E
G
Fig. 6. Effects of IL1b, tunicamycin, and salubrinal on the mRNA levels of MMPs. (AeD) Mess
(EeH) Messenger RNA levels of MMP1, MMP2, MMP3, and MMP14 in response to tunicamreduced IL1b-driven elevation to the basal level lower than that of
control cells. The observed increase in the MMP13 mRNA level was
accompaniedwith anelevationof p-p38MAPKaswell asp-NFkBp65
and p-IKKa/b, and 10 mM salubrinal reduced the levels of those
phosphorylated isoforms [Fig. 4(E and F)]. No changes in the level of
p-eIF2awere observed within 60 min (data not shown).B
D
F
H
enger RNA levels of MMP1, MMP2, MMP3, and MMP14 in response to IL1b, respectively.
ycin, respectively.
K. Hamamura et al. / Osteoarthritis and Cartilage 21 (2013) 764e772 771Effects of silencing NFkB p65 on the phosphorylation levels of p38
MAPK and eIF2a
To examine interactions of NFkB signaling to the phosphoryla-
tion of p38 MAPK and eIF2a, the protein level of NFkB p65 was
signiﬁcantly reduced by siRNA speciﬁc to NFkB p65 [Fig. 5(A)]. In
the absence of TNFa, the effects of silencing NFkB p65 on the level
of p-p38 MAPK and p-eIF2a were not detectable [Fig. 5(B)]. In
response to TNFa, however, the TNFa-driven elevation of p-p38
MAPK was suppressed by NFkB siRNA [Fig. 5(B)]. Control cells,
transfected with negative control siRNA, incubation with TNFa
signiﬁcantly increased MMP13 activity and administration of
salubrinal reduced it to the basal level [Fig. 5(C)]. However, cells
transfected with NFkB siRNA showed reduction in TNFa-driven
upregulation of MMP13 activity and the effect of salubrinal was not
smaller than that of the control cells [Fig. 5(C)].
Effects of salubrinal on the mRNA expression of MMP1, MMP2,
MMP3, and MMP14
In response to 1 ng/ml IL1b and 1 mg/ml tunicamycin, the mRNA
levels of MMP1, MMP2, and MMP14 were not altered, but the level
of MMP3 mRNAwas elevated [Fig. 6]. In all cases, administration of
salubrinal at 5 or 10 mM did not signiﬁcantly change their mRNA
levels.
Discussion
We present in this study that salubrinal suppressed the level of
MMP13 mRNA, which was induced by the stress to the ER and in-
ﬂammatory cytokines. Salubrinal also decreased cytokine-driven
degenerative activity of MMP13. All three inducers in this study
(tunicamycin, TNFa, and IL1b) elevated p-p38 MAPK, while p-NFkB
p65 was elevated by TNFa and IL1b but not by tunicamycin.
Consistent with the involvement of NFkB signaling, salubrinal
decreased the level of p-IKK that was known to downregulate the
NFkB inhibitor, IkB18. Silencing NFkB p65 by RNA interference
reduced TNFa-driven upregulation of MMP13 activity, and atten-
uated salubrinal’s effect on TNFa. Collectively, the results demon-
strate that salubrinal is capable of downregulating MMP13 by
suppressing p38 MAPK and NFkB [Fig. 7].
Although the role of p38 MAPK and NFkB in the regulation of
MMP13 has been documented7, salubrinal’s mechanism of action
on these pathways has not been understood. Salubrinal is a selec-
tive inhibitor of a phosphatase of eIF2a, and it is reported toFig. 7. Potential signaling pathways involved in the regulation of MMP13 in response
to ER stress and inﬂammatory cytokines.increase the level of p-eIF2a10,19. Using cortical neuronal cells iso-
lated from rats, salubrinal has been shown to attenuate b-amyloid-
induced neuronal death through the inhibition of NFkB signaling20.
In this neuronal study linked to Alzheimer’s disease, salubrinal
exerts its effects through the inhibition of IKK activation, IkB
degradation, and the subsequent NFkB p65 activation without
altering the phosphorylation of eIF2a. In our MMP13 study using
C28/I2 chondrocytes we also observed the inhibition of NFkB
signaling by salubrinal.
The alteration in p-eIF2a was not considered as a trigger of p38
MAPK andNFkB pathways.We observed that it tookw1 h andw5 h
to induce a detectable increase in p-eIF2a in response to tunica-
mycin and inﬂammatory cytokines, respectively. However, the
elevation in p-p38 MAPK and p-NFkB was observed in 15 min.
Furthermore,Western blot analysis with siRNA speciﬁc to NFkB p65
indicated that NFkB signaling was linked to p38 MAPK but not to
eIF2a. To explain the observed effects of salubrinal, a potential
mechanism may include inhibition of de-phosphorylation of p-p38
MAPK, p-IKKa/b, and/or p-NFkB through PP1, an eIF2a-targeted
phosphatase complex21,22. Another mechanism might be based on
a potential interaction of salubrinal with phosphatases speciﬁc to
p38 MAPK, IKKa/b, and/or NFkB. Further studies are necessary to
determine a potential target of salubrinal, which may suppress
NFkB and p38 MAPK signaling that is not directly linked to eIF2a
phosphorylation.
MMP13 is a major MMP in osteoarthritis, in which the levels of
other MMPs and a disintegrin and metalloproteinase with throm-
bospondin motifs (ADAMTSs) are elevated23,24. In this study, we
focused onMMP13 since it is themost highly expressed collagenase
in patients with osteoarthritis and its substrates include not only
collagen but also aggrecan. Since it is reported that broad-spectrum
MMP inhibition may cause musculoskeletal side effects25, we
examined the effects of salubrinal on other MMPs including MMP1,
MMP2, MMP3, and MMP14 in the presence of IL1b and tunicamy-
cin. Although IL1b elevated the mRNA level of MMP3, the mRNA
levels of these four MMPs were not altered by tunicamycin or
salubrinal. Further analysis of salubrinal’s suppressive effect on
other MMPs and ADAMTSs is necessary for determining its selec-
tivity and potential therapeutic usage to osteoarthritis.
There are multiple strategies to prevent degradation of joint
tissues, including gentle mechanical stimulation and administra-
tion of antibodies directed to inﬂammatory cytokines as well as
synthetic chemical agents. Efﬁcacy of salubrinal for diseases and
disorders including diabetes10, Alzheimer diseases20, and osteo-
porosis14 has been investigated. Herein, we examined a potential
therapeutic role of salubrinal in maintenance of joint tissues
focusing on blocking expression and degenerative activity of
MMP13. There is a possibility that administration of salubrinal not
only blocks osteoporotic bone loss but also prevents degradation of
arthritic joint tissues. It is necessary to examine the responses to
salubrinal using osteoarthritis animal models and determine its
effects on other MMPs and ADAMTSs. In summary, we demon-
strated that the administration of salubrinal decreased the level of
MMP13 mRNA as well as its degenerative activity. The results were
consistent with the mechanism in which salubrinal inhibits p38
MAPK and NFkB signaling pathways.
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